Effectiveness of Anti-Psychotic in GPs Setting (Serenity)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00543088
First received: October 11, 2007
Last updated: April 22, 2009
Last verified: April 2009
  Purpose

Evaluating the effectiveness of atypical antipsychotics in the community - a prospective, multicentre, observational study to evaluate the impact on Quality of Life of GP-based management of antipsychotic treatment in Belgium


Condition
Schizophrenia
Bipolar Disorder

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: SERENITY: Evaluating the Effectiveness of Atypical Antipsychotics in the Community - a Prospective, Multicentre, Observational Study to Evaluate the Impact on Quality of Life of GP-Bases Management of Antipsychotic Treatment in Belgium.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • to evaluate the patient's functioning, by measuring the Quality of Life. Quality of Life will be assessed by the Q-LES-Q-16 (PRO).

Secondary Outcome Measures:
  • The clinical efficacy & tolerability of atypical antipsychotics as assessed by the Clinical Global Impression(CGI) & Patient Global Impression of Change(PGIC)scores.
  • The wellbeing of the patients taking atypical antipsychotics as assessed by the Sheehan Disability Scale(SDS)

Estimated Enrollment: 250
Study Start Date: January 2007
Study Completion Date: June 2008
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients diagnosed with Schizophrenia or Bipolar Disorder (currently in a manic episode)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00543088

  Hide Study Locations
Locations
Belgium
Research Site
Baudour, Belgium
Research Site
Beyne-Heysay, Belgium
Research Site
Bomal-sur-Ourthe, Belgium
Research Site
Bredene, Belgium
Research Site
Bruxelles, Belgium
Research Site
Esen, Belgium
Research Site
Evere, Belgium
Research Site
Gingelom, Belgium
Research Site
Gouy-Lez-Pieton, Belgium
Research Site
Grace-Hollogne, Belgium
Research Site
Gullegem, Belgium
Research Site
Harelbeke, Belgium
Research Site
Harre, Belgium
Research Site
Hotton, Belgium
Research Site
Houtvenne, Belgium
Research Site
Incourt, Belgium
Research Site
Ixelles, Belgium
Research Site
Jalhay, Belgium
Research Site
Jette, Belgium
Research Site
Keumiee, Belgium
Research Site
Lembeke, Belgium
Research Site
Limbourg, Belgium
Research Site
Li�ege, Belgium
Research Site
Longueville, Belgium
Research Site
Lovendegem, Belgium
Research Site
Malmedy, Belgium
Research Site
Mechelen, Belgium
Research Site
Monceau sur Sambre, Belgium
Research Site
Montignies sur sambre, Belgium
Research Site
Moorsel, Belgium
Research Site
Moorseled, Belgium
Research Site
Mouscron, Belgium
Research Site
Namur, Belgium
Research Site
Oostrozebeke, Belgium
Research Site
Ostende, Belgium
Research Site
Oudenaarde, Belgium
Research Site
Poperinge, Belgium
Research Site
Ransart, Belgium
Research Site
Roux, Belgium
Research Site
Ruisbroek, Belgium
Research Site
Schaerbeek, Belgium
Research Site
Spa, Belgium
Research Site
Staden, Belgium
Research Site
Theux, Belgium
Research Site
Tilleur, Belgium
Research Site
Torhout, Belgium
Research Site
Tubize, Belgium
Research Site
Verviers, Belgium
Research Site
Veurne, Belgium
Research Site
Wachtebeke, Belgium
Research Site
Willebroek, Belgium
Research Site
Wilrijk, Belgium
Research Site
Woluwe-St-Lambert, Belgium
Research Site
Zeebrugge, Belgium
Research Site
Zichem, Belgium
Research Site
Zomergem, Belgium
Research Site
Zonnebeke, Belgium
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Pitchot W Pr ULg
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00543088     History of Changes
Other Study ID Numbers: SRP-NB-SER-2006/1
Study First Received: October 11, 2007
Last Updated: April 22, 2009
Health Authority: Not require for this study:

Keywords provided by AstraZeneca:
Schizophrenia
Bipolar Disorder
manic episode
atypical antipsychotic
Schizophrenia or Bipolar Disorder (currently in a manic episode)

Additional relevant MeSH terms:
Bipolar Disorder
Schizophrenia
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on July 22, 2014